Following participation in this activity the learner should be able to:
- List 4 diagnostic criteria for Dravet syndrome in both pediatric and adult patients.
- Describe the first and second line treatments for Dravet syndrome, and which medications should be avoided in patients with Dravet syndrome.
- Describe ways to effectively utilize telemedicine approaches to manage patients with complex needs.
- Develop a seizure rescue plan and list currently available seizure rescue medications for Dravet syndrome.
- Discuss how a neurologist might manage co-morbidities that extend beyond the CNS.
- Describe how clinicians can support the transition from pediatric to adult care.
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.
Planning Committee, Faculty, Reviewers’ Disclosures of Financial Relationships
In accordance with the ACCME Standards for Commercial Support, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with a commercial interest. Unless otherwise indicated, none of the planners or faculty of this activity have any relevant relationships to disclose. The following individuals contributed to this activity’s content.
Planning Committee and Faculty
M. Scott Perry, MD, Cook Children’s Medical Center
Dr. Perry has disclosed the following relevant relationships:
Advisory Board/Consultant: Stoke Therapeutics, Encoded Therapeutics, Greenwich, Zogenix, Neurelis, Biocodex
Speakers’ Bureau: Zogenix, Biocodex
Research (paid to Cook Children’s Medical Center): Zogenix, Greenwich, Stoke, Marinus, Ovid
Danielle Andrade, MD, MSc, FRCPC, University of Toronto
Dr. Andrade has disclosed the following relevant relationships:
Consultant Eisai, Advisory Board dravet.ca, Advisory Board Stoke
Elaine Wirrell, MD, Mayo Clinic
Dr. Wirrell has disclosed the following relevant relationships:
Biocodex, Biomarin, and Encoded Therapeutics: Consulting fees.
Kelly Knupp, MD, MSCS, Children’s Hospital Colorado
Dr. Knupp has disclosed the following relevant relationships:
Zogenix, Biomarin, Stoke, Arena, and Epygenix: Consulting fees.
Zogenix, Stoke, West Pharmaceuticals, and Eisai: Research
Ingrid Scheffer, AO, MB, BS, PhD, FRACP, FAES, FAHMS, FAA, FRS, University of Melbourne & Austin Health
Prof Scheffer has disclosed the following relevant relationships:
Honoraria, Membership on advisory committees/boards, review panels: BioMarin, UCB, Chiesi Australia, and Encoded Therapeutics
Remuneration: Biocodex, BioMarin, UCB, and Care Beyond Diagnosis
Joseph Sullivan, MD, FAES, UCSF Pediatric Epilepsy Center
Dr. Sullivan has disclosed the following relevant relationships:
Research: Zogenix and Stoke
Consulting fee & ownership interest: Epygenix
Ashley Wood, LCSW, The Life Support Project
No commercial interest
Ian Miller, MD, Nicklaus Children’s Hospital
Dr. Miller has disclosed the following relevant relationships:
Honoraria, Membership on advisory committees/boards, review panels: Greenwich Biosciences, Zogenix, Biomarin, Neurelis
Honoraria, In-kind donations: Upsher-Smith
Dravet Syndrome Foundation Staff Planners
Veronica Hood, PhD, Dravet Syndrome Foundation
No commercial interest
Mary Anne Meskis, Dravet Syndrome Foundation
No commercial interest
Jay Salpekar, MD, Kennedy Krieger Institute
Dr. Salpekar has disclosed the following relevant relationships:
Lundbeck: Investigator initiated study- research funding to institution only; contracted research
Elaine Sing-Was Seto, MD, PhD, Texas Children’s Hospital
No Commercial Interest
Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.
This other activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Epilepsy Society and the Dravet Syndrome Foundation. The American Epilepsy Society is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Category 1 Credit™ Designation Statement
The American Epilepsy Society designates this other activity for a maximum of 7 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.
Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the Dravet Syndrome Foundation and the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.
If you have questions regarding this educational activity, please contact the Dravet Syndrome Foundation, email@example.com.